Boston, MA (UroToday.com) This late-breaking abstract was presented to report the results of the Phase III double-blind RCT of a comparison between the use of aquablation (or water stream to ablate/resect) for prostate resection and the standard-of-care transurethral resection of the prostate (TURP). Overall, 275 men with moderate to severe LUTS due to BPH were considered for enrollment in this study, titled WATER (Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue). Patients with prior prostate surgery, prostate cancer, or neurogenic bladder were excluded. A total of 181 patients were included in the study, with 116 in the aquablation arm and 65 in the TURP arm.
Primary endpoints of the study were 3-month safety (defined as proportion difference in persistent Clavien grade 1 event or grade 2 or higher event by month 3) and 6-month efficacy (defined in IPSS at 6 months. Both were tested for non-inferiority. Aquablation was found to be superior in terms of primary safety, ejaculatory function postoperatively, incontinence severity; it was non-inferior in terms of primary efficacy, and it resulted in statistically significantly greater urine flow. Upon subgroup analysis of patients with >50g prostate size, aquablation was superior in regard to primary safety (Clavien complications: 19% Aquablation vs 43% TURP, p<0.01) and efficacy (IPSS drop: 17 points Aquablation vs 13 points TURP, p=0.01). Furthermore, the resection time for aquablation (4 minutes) was significantly shorter than TURP (27 minutes), and was independent of gland volume.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new
treatments, enrolling clinical trials, screening and surveillance
recommendations along with updated guidelines. Join us as one of our
subscribers who rely on UroToday as their must-read source for the
latest news and data on drugs. Sign up today for blogs, video
conversations, conference highlights and abstracts from peer-review
publications by disease and condition delivered to your inbox and read
on the go.
This promising technology may result in a substantially improved method for surgically treating patients with symptomatic BPH.
Authors: Claus Roerhborn, MD
Affiliation: Department of Urology, University of Texas Southwestern
Written By: Shoaib Safiullah, MS4 for UroToday.com
at the 2017 AUA Annual Meeting - May 12 - 16, 2017 – Boston, Massachusetts, USA